# Filing Detail

Form PREM14C - Preliminary information statements relating to merger or acquisition:
SEC Accession No. 0001213900-26-005174
Filing Date
2026-01-16
Accepted
2026-01-16 16:35:58
Documents
15
Period of Report
2026-01-16

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | INFORMATION STATEMENT | ea0272926-01.htm | PREM14C | 11281088
2 | FILING FEE IXBRL | ea027292601ex-fee_apimeds.htm iXBRL | EX-FILING FEES | 11037
3 | GRAPHIC | tapimeds_logo.jpg | GRAPHIC | 128942
4 | GRAPHIC | ttable_01.jpg | GRAPHIC | 974757
5 | GRAPHIC | tflowchart_001.jpg | GRAPHIC | 123378
| Complete submission text file | 0001213900-26-005174.txt |  | 13094758

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
17 | EXTRACTED XBRL INSTANCE DOCUMENT | ea027292601ex-fee_apimeds_htm.xml | XML | 3744

Mailing Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747
Business Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747 848-201-5010
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PREM14C | Act: 34 | File No.: 001-42545 | Film No.: 26539966
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)